Advances in therapeutic strategies for the treatment of pruritus

References

• Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol. 2015 May 1. [Epub ahead of print].
   PubMedGoogle Scholar
• Stander S, Weisshaar E, Mettang T, et al. Clinical classification of itch: A position paper of the international forum for the study of itch. Acta Derm Venereol. 2007;87(4):291–294.
   PubMed Web of Science ®Google Scholar
• Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol. 2009;89(4):339–350.
   PubMed Web of Science ®Google Scholar
• Leslie TA, Greaves MW, Yosipovitch G. Current topical and systemic therapies for itch. Handb Exp Pharmacol. 2015;226:337–356.
   PubMedGoogle Scholar
• Young TA, Patel TS, Camacho F, et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. J Dermatolog Treat. 2009;20(2):76–81.
   PubMed Web of Science ®Google Scholar
• Patel T, Yosipovitch G. Therapy of pruritus. Expert Opin Pharmacother. 2010;11(10):1673–1682.
   PubMed Web of Science ®Google Scholar
• Valdes-Rodriguez R, Kaushik SB, Yosipovitch G. Transient receptor potential channels and dermatological disorders. Curr Top Med Chem. 2013;13(3):335–343.
   PubMed Web of Science ®Google Scholar
• Papoiu AD, Chaudhry H, Hayes EC, et al. TriCalm((R)) hydrogel is significantly superior to 2% diphenhydramine and 1% hydrocortisone in reducing the peak intensity, duration, and overall magnitude of cowhage-induced itch. Clin Cosmet Investig Dermatol. 2015;8:223–229.
   PubMedGoogle Scholar
• Eberlein B, Eicke C, Reinhardt HW, et al. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008;22(1):73–82.
   PubMed Web of Science ®Google Scholar
• Kurtz ES, Wallo W. Colloidal oatmeal: history, chemistry and clinical properties. J Drugs Dermatol. 2007;6(2):167–170.
   PubMedGoogle Scholar
• Griffin JR, Davis MD. Amitriptyline/ketamine as therapy for neuropathic pruritus and pain secondary to herpes zoster. J Drugs Dermatol. 2015;14(2):115–118.
   PubMed Web of Science ®Google Scholar
• Poterucha TJ, Murphy SL, Davis MD, et al. Topical amitriptyline-ketamine for the treatment of brachioradial pruritus. JAMA Dermatol. 2013;149(2):148–150.
   PubMed Web of Science ®Google Scholar
• Poterucha TJ, Murphy SL, Sandroni P, et al. Topical amitriptyline combined with topical ketamine for the management of recalcitrant localized pruritus: A retrospective pilot study. J Am Acad Dermatol. 2013;69(2):320–321.
   PubMed Web of Science ®Google Scholar
• Kircik LH. Efficacy and onset of action of hydrocortisone acetate 2.5% and pramoxine hydrochloride 1% lotion for the management of pruritus: results of a pilot study. J Clin Aesthet Dermatol. 2011;4(2):48–50.
   PubMedGoogle Scholar
• Misery L, Erfan N, Castela E, et al. Successful treatment of refractory neuropathic pruritus with capsaicin 8% patch: a bicentric retrospective study with long-term follow-up. Acta Derm Venereol. 2015;5(7):864–865.
   Web of Science ®Google Scholar
• Yosipovitch G, Sugeng MW, Chan YH, et al. The effect of topically applied aspirin on localized circumscribed neurodermatitis. J Am Acad Dermatol. 2001;45(6):910–913.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Bernhard JD. Clinical practice. chronic pruritus. N Engl J Med. 2013;368(17):1625–1634.
   PubMed Web of Science ®Google Scholar
• Uzaraga I, Gerbis B, Holwerda E, et al. Topical amitriptyline, ketamine, and lidocaine in neuropathic pain caused by radiation skin reaction: A pilot study. Support Care Cancer. 2012;20(7):1515–1524.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Maibach HI. Effect of topical pramoxine on experimentally induced pruritus in humans. J Am Acad Dermatol. 1997;37(2 Pt 1):278–280.
   PubMed Web of Science ®Google Scholar
• Zeidler C, Luling H, Dieckhofer A, et al. Capsaicin 8% cutaneous patch: a promising treatment for brachioradial pruritus? Br J Dermatol. 2015;172(6):1669–1671.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Maibach HI, Rowbotham MC. Effect of EMLA pre-treatment on capsaicin-induced burning and hyperalgesia. Acta Derm Venereol. 1999;79(2):118–121.
   PubMed Web of Science ®Google Scholar
• Gibson RA, Robertson J, Mistry H, et al. A randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers. PLoS One. 2014;9(7):e100610.
   Google Scholar
• Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014;20(5):22608.
   PubMedGoogle Scholar
• Anacor pharmaceuticals announces positive results from phase 2 dose-ranging study of AN2728 in adolescents with atopic dermatitis (NASDAQ:ANAC) [Internet]; [ cited 2015 Sep 14]. Available from: http://investor.anacor.com/releasedetail.cfm?releaseid=750026.
   Google Scholar
• Clinicaltrials.gov. Safety and efficacy of AN2728 topical ointment, 2% in children, adolescents, and adults (aged 2 years and older) with atopic dermatitis [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02118792?term=an2728&rank=3
   Google Scholar
• Zhai H, Hannon W, Hahn GS, et al. Strontium nitrate decreased histamine-induced itch magnitude and duration in man. Dermatology. 2000;200(3):244–246.
   PubMed Web of Science ®Google Scholar
• Papoiu AD, Valdes-Rodriguez R, Nattkemper LA, et al. A novel topical formulation containing strontium chloride significantly reduces the intensity and duration of cowhage-induced itch. Acta Derm Venereol. 2013;93(5):520–526.
   PubMed Web of Science ®Google Scholar
• Yamaguchi J, Aihara M, Kobayashi Y, et al. Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis. J Dermatol Sci. 2009;53(1):48–54.
   PubMed Web of Science ®Google Scholar
• Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95(5):542–548.
   PubMed Web of Science ®Google Scholar
• Senba E, Katanosaka K, Yajima H, et al. The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers. Neurosci Res. 2004;50(3):257–262.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Pan WH, Wang XR, et al. Tryptase and protease-activated receptor-2 stimulate scratching behavior in a murine model of ovalbumin-induced atopic-like dermatitis. Int Immunopharmacol. 2015;28(1):507–512.
   PubMed Web of Science ®Google Scholar
• Ring J, Mohrenschlager M, Henkel V. The US FDA ‘black box’ warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf. 2008;31(3):185–198.
   PubMed Web of Science ®Google Scholar
• Van Leent EJ, Ebelin ME, Burtin P, et al. Low systemic exposure after repeated topical application of pimecrolimus (elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology. 2002;204(1):63–68.
   PubMed Web of Science ®Google Scholar
• Margolis DJ, Abuabara K, Hoffstad OJ, et al. Association between malignancy and topical use of pimecrolimus. JAMA Dermatol. 2015;151(6):594–599.
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Arai I, Futaki N, et al. COX-1 inhibition enhances scratching behaviour in NC/nga mice with atopic dermatitis. Exp Dermatol. 2006;15(8):582–588.
   PubMed Web of Science ®Google Scholar
• Inoue T, Sugimoto M, Sakurai T, et al. Modulation of scratching behavior by silencing an endogenous cyclooxygenase-1 gene in the skin through the administration of siRNA. J Gene Med. 2007;9(11):994–1001.
   PubMed Web of Science ®Google Scholar
• Stander S, Schmelz M, Metze D, et al. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci. 2005;38(3):177–188.
   PubMed Web of Science ®Google Scholar
• Toth BI, Szallasi A, Biro T. Transient receptor potential channels and itch: how deep should we scratch? Handb Exp Pharmacol. 2015;226:89–133.
   PubMedGoogle Scholar
• van der Stelt M, Trevisani M, Vellani V, et al. Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. Embo J. 2005;24(17):3026–3037.
   PubMed Web of Science ®Google Scholar
• Stander S, Reinhardt HW, Luger TA. Topical cannabinoid agonists: an effective new possibility for treating chronic pruritus. Hautarzt. 2006;57(9):801–807.
   PubMed Web of Science ®Google Scholar
• Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat. 2005;13(2):97–103.
   PubMedGoogle Scholar
• Sur R, Nigam A, Grote D, et al. Avenanthramides, polyphenols from oats, exhibit anti-inflammatory and anti-itch activity. Arch Dermatol Res. 2008;300(10):569–574.
   PubMed Web of Science ®Google Scholar
• Leslie TA, Greaves MW, Yosipovitch G. Current topical and systemic therapies for itch. Handb Exp Pharmacol. 2015;226:337–356.
   PubMedGoogle Scholar
• Zhai H, Frisch S, Pelosi A, et al. Antipruritic and thermal sensation effects of hydrocortisone creams in human skin. Skin Pharmacol Appl Skin Physiol. 2000;13(6):352–357.
   PubMedGoogle Scholar
• Wilson SR, Gerhold KA, Bifolck-Fisher A, et al. TRPA1 is required for histamine-independent, mas-related G protein-coupled receptor-mediated itch. Nat Neurosci. 2011;14(5):595–602.
   PubMed Web of Science ®Google Scholar
• Chen J, Hackos DH. TRPA1 as a drug target–promise and challenges. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(4):451–463.
   PubMed Web of Science ®Google Scholar
• Denda M, Tsutsumi M. Roles of transient receptor potential proteins (TRPs) in epidermal keratinocytes. Adv Exp Med Biol. 2011;704:847–860.
   PubMed Web of Science ®Google Scholar
• Yamamoto-Kasai E, Imura K, Yasui K, et al. TRPV3 as a therapeutic target for itch. J Invest Dermatol. 2012;132(8):2109–2112.
   PubMed Web of Science ®Google Scholar
• Wilson SR, Bautista DM. Role of transient receptor potential channels in acute and chronic itch. In: Carstens E, Akiyama T, editors. Itch: mechanisms and treatment. Boca Raton (FL): Taylor & Francis Group, LLC; 2014.
   Google Scholar
• Wallengren J. Topical aprepitant in clinical and experimental pruritus. Arch Dermatol. 2012;148(8):957–959.
   PubMedGoogle Scholar
• Liu Q, Weng HJ, Patel KN, et al. The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia. Sci Signal. 2011;4(181):ra45.
   PubMed Web of Science ®Google Scholar
• Reddy VB, Iuga AO, Shimada SG, et al. Cowhage-evoked itch is mediated by a novel cysteine protease: a ligand of protease-activated receptors. J Neurosci. 2008;28(17):4331–4335.
   PubMed Web of Science ®Google Scholar
• Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated receptor-2 mediates itch: A novel pathway for pruritus in human skin. J Neurosci. 2003;23(15):6176–6180.
   PubMed Web of Science ®Google Scholar
• Reddy VB, Sun S, Azimi E, et al. Redefining the concept of protease-activated receptors: cathepsin S evokes itch via activation of mrgprs. Nat Commun. 2015;6:7864.
   PubMed Web of Science ®Google Scholar
• Kim N, Bae KB, Kim MO, et al. Overexpression of cathepsin S induces chronic atopic dermatitis in mice. J Invest Dermatol. 2012;132(4):1169–1176.
   PubMed Web of Science ®Google Scholar
• Schonefuss A, Wendt W, Schattling B, et al. Upregulation of cathepsin S in psoriatic keratinocytes. Exp Dermatol. 2010;19(8):e80–8.
   PubMed Web of Science ®Google Scholar
• Stander S, Weisshaar E, Raap U. Emerging drugs for the treatment of pruritus. Expert Opin Emerg Drugs. 2015;20(3):515–521.
   PubMed Web of Science ®Google Scholar
• Mansour-Ghanaei F, Taheri A, Froutan H, et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol. 2006;12(7):1125–1128.
   PubMed Web of Science ®Google Scholar
• Peer G, Kivity S, Agami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet. 1996;348(9041):1552–1554.
   PubMed Web of Science ®Google Scholar
• Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol. 2006;54(3):527–531.
   PubMed Web of Science ®Google Scholar
• Inui S. Nalfurafine hydrochloride to treat pruritus: a review. Clin Cosmet Investig Dermatol. 2015;8:249–255.
   PubMed Web of Science ®Google Scholar
• Ehrchen J, Stander S. Pregabalin in the treatment of chronic pruritus. J Am Acad Dermatol. 2008;58(2 Suppl):S36–7.
   PubMed Web of Science ®Google Scholar
• Gunal AI, Ozalp G, Yoldas TK, et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant. 2004;19(12):3137–3139.
   PubMed Web of Science ®Google Scholar
• Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol. 2004;50(6):889–891.
   PubMed Web of Science ®Google Scholar
• Stander S, Bockenholt B, Schurmeyer-Horst F, et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol. 2009;89(1):45–51.
   PubMed Web of Science ®Google Scholar
• Mayo MJ, Handem I, Saldana S, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45(3):666–674.
   PubMed Web of Science ®Google Scholar
• Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Engl J Med. 2009;361(14):1415–1416.
   PubMed Web of Science ®Google Scholar
• Stander S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5(6):e10968.
   PubMed Web of Science ®Google Scholar
• Roekevisch E, Spuls PI, Kuester D, et al. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014;133(2):429–438.
   PubMed Web of Science ®Google Scholar
• Maley A, Swerlick RA. Azathioprine treatment of intractable pruritus: a retrospective review. J Am Acad Dermatol. 2015;73(3):439–443.
   PubMed Web of Science ®Google Scholar
• Haeck IM, Knol MJ, Ten Berge O, et al. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol. 2011;64(6):1074–1084.
   PubMed Web of Science ®Google Scholar
• Kanwar AJ, De D. Methotrexate for treatment of lichen planus: Old drug, new indication. J Eur Acad Dermatol Venereol. 2013;27(3):e410–3.
   PubMed Web of Science ®Google Scholar
• Maurer T, Poncelet A, Berger T. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. Arch Dermatol. 2004;140(7):845–849.
   PubMedGoogle Scholar
• Kanavy H, Bahner J, Korman NJ. Treatment of refractory prurigo nodularis with lenalidomide. Arch Dermatol. 2012;148(7):794–796.
   PubMedGoogle Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409.
   Google Scholar
• Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101–109.
   PubMed Web of Science ®Google Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015 Sep 10. [Epub ahead of print].
   Google Scholar
• Pauli-Magnus C, Mikus G, Alscher DM, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol. 2000;11(3):514–519.
   PubMed Web of Science ®Google Scholar
• Jung SI, Seo CH, Jang K, et al. Efficacy of naltrexone in the treatment of chronic refractory itching in burn patients: preliminary report of an open trial. J Burn Care Res. 2009;30(2):257,60. discussion 261
   Google Scholar
• Cowan A, Yosipovitch G. Preface. Handb Exp Pharmacol. 2015;226:v–vi.
   PubMedGoogle Scholar
• Cara therapeutics announces positive results from phase 2 trial in uremic pruritus (NASDAQ:CARA) [Internet]; [ cited 2015 Sep 14]. Available from: http://ir.caratherapeutics.com/releasedetail.cfm?releaseid=923457.
   Google Scholar
• Papoiu AD, Kraft RA, Coghill RC, et al. Butorphanol suppression of histamine itch is mediated by nucleus accumbens and septal nuclei: a pharmacological fMRI study. J Invest Dermatol. 2015;135(2):560–568.
   PubMed Web of Science ®Google Scholar
• Liao CC, Chang CS, Tseng CH, et al. Efficacy of intramuscular nalbuphine versus diphenhydramine for the prevention of epidural morphine-induced pruritus after cesarean delivery. Chang Gung Med J. 2011;34(2):172–178.
   PubMedGoogle Scholar
• Clinicaltrials.gov. Study of nalbuphine HCL ER tablets in hemodialysis patients with uremic pruritus [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02143648?term=nalbuphine+pruritus&rank=1.
   Google Scholar
• Clinicaltrials.gov study of nalbuphine HCL ER tablets in patients with prurigo nodularis [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02174419?term=nalbuphine+pruritus&rank=5
   Google Scholar
• Tioga pharmaceuticals announces initiation of phase 2 clinical study of asimadoline in… – SAN DIEGO, June 11, 2015 /PRNewswire/ – [Internet]; [ cited 2015 Sep 22]. Available from: http://www.prnewswire.com/news-releases/tioga-pharmaceuticals-announces-initiation-of-phase-2-clinical-study-of-asimadoline-in-patients-with-pruritus-associated-with-atopic-dermatitis-300097588.html
   Google Scholar
• Roberson DP, Gudes S, Sprague JM, et al. Activity-dependent silencing reveals functionally distinct itch-generating sensory neurons. Nat Neurosci. 2013;16(7):910–918.
   PubMed Web of Science ®Google Scholar
• Ikoma A, Steinhoff M, Stander S, et al. The neurobiology of itch. Nat Rev Neurosci. 2006;7(7):535–547.
   PubMed Web of Science ®Google Scholar
• Davis MP, Frandsen JL, Walsh D, et al. Mirtazapine for pruritus. J Pain Symptom Manage. 2003;25(3):288–291.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Girouard SD, Carlberg VM, et al. Effective use of mirtazapine for refractory pruritus associated with carcinoma en cuirasse. BMJ Support Palliat Care. 2014 Dec 16. [Epub ahead of print].
   Google Scholar
• Namaka M, Gramlich CR, Ruhlen D, et al. A treatment algorithm for neuropathic pain. Clin Ther. 2004;26(7):951–979.
   PubMed Web of Science ®Google Scholar
• Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2006;55(3):543–544.
   PubMed Web of Science ®Google Scholar
• Stander S, Luger TA. NK-1 antagonists and itch. Handb Exp Pharmacol. 2015;226:237–255.
   PubMedGoogle Scholar
• Clinicaltrials.gov. Effect of neurokinin-1 receptor (NK1R) antagonism on pruritus in patients with sezary syndrome [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01625455?term=aprepitant+sezary&rank=1
   Google Scholar
• Press release | tigercat | chronic pruritus [Internet]; [ cited 2015 Sep 14]. Available from: http://tonydimatteo.com/tigercat/category/press-release/.
   Google Scholar
• Clinicaltrials.gov. A randomized placebo-controlled study of the neurokinin-1 (NK1) receptor antagonist VPD-737 prurigo nodularis (PN) [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02196324?term=serlopitant&rank=1
   Google Scholar
• Vanda pharmaceuticals announces tradipitant phase II proof of concept study results for chronic… – WASHINGTON, march 4, 2015 /PRNewswire/ – [Internet]; [ cited 2015 Sep 14]. Available from: http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-tradipitant-phase-ii-proof-of-concept-study-results-for-chronic-pruritus-in-atopic-dermatitis-300045700.html.
   Google Scholar
• Pacor ML, Di Lorenzo G, Martinelli N, et al. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clin Exp Allergy. 2004;34(4):639–645.
   PubMed Web of Science ®Google Scholar
• Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol. 2000;142(1):52–58.
   PubMed Web of Science ®Google Scholar
• Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol. 2002;147(2):324–330.
   PubMed Web of Science ®Google Scholar
• Neuber K, Schwartz I, Itschert G, et al. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol. 2000;143(2):385–391.
   PubMed Web of Science ®Google Scholar
• Ballester I, Silvestre JF, Perez-Crespo M, et al. Severe adult atopic dermatitis: treatment with mycophenolate mofetil in 8 patients. Actas Dermosifiliogr. 2009;100(10):883–887.
   PubMedGoogle Scholar
• Zimmerman AB, Berger EM, Elmariah SB, et al. The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients. J Am Acad Dermatol. 2012;66(5):767–770.
   PubMed Web of Science ®Google Scholar
• Daly BM, Shuster S. Antipruritic action of thalidomide. Acta Derm Venereol. 2000;80(1):24–25.
   PubMed Web of Science ®Google Scholar
• Ladizinski B, Shannon EJ, Sanchez MR, et al. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. J Drugs Dermatol. 2010;9(7):814–826.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868–887.
   PubMed Web of Science ®Google Scholar
• O’Donoghue M, Tharp MD. Antihistamines and their role as antipruritics. Dermatol Ther. 2005;18(4):333–340.
   PubMedGoogle Scholar
• Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. A study of lebrikizumab in patients with persistent moderate to severe atopic dermatitis [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02340234?term=lebrikizumab&rank=3
   Google Scholar
• Raap U, Wichmann K, Bruder M, et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol. 2008;122(2):421–423.
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Muller A, Lauerma AI, et al. IL-31: A new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411–417.
   PubMed Web of Science ®Google Scholar
• Cedeno-Laurent F, Singer EM, Wysocka M, et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol. 2015;158(1):1–7.
   PubMed Web of Science ®Google Scholar
• Grimstad O, Sawanobori Y, Vestergaard C, et al. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/nga mice: a model of atopic dermatitis. Exp Dermatol. 2009;18(1):35–43.
   PubMed Web of Science ®Google Scholar
• Nemoto O, Furue M, Nakagawa H, et al. The first trial of CIM331, a humanized anti-human IL-31 receptor A antibody, for healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomised, double-blind, placebo-controlled study. Br J Dermatol. 2015 Sep 26. [Epub ahead of print].
   Google Scholar
• Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160(2):319–324.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
   PubMed Web of Science ®Google Scholar
• Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135(2):324–336.
   PubMed Web of Science ®Google Scholar
• Puya R, Alvarez-Lopez M, Velez A, et al. Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol. 2012;51(1):115–116.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. A study of ustekinumab in adult japanese participants with severe atopic dermatitis [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01945086?term=ustekinumab+atopic+dermatitis&rank=1
   Google Scholar
• Kim DH, Park KY, Kim BJ, et al. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol. 2013;38(5):496–500.
   PubMed Web of Science ®Google Scholar
• Montes-Torres A, Llamas-Velasco M, Perez-Plaza A, et al. Biological treatments in atopic dermatitis. J Clin Med. 2015;4(4):593–613.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Role of anti-IgE in severe childhood eczema (ADAPT) [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02300701?term=omalizumab+atopic+dermatitis&rank=4
   Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49.
   PubMed Web of Science ®Google Scholar
• Samrao A, Berry TM, Goreshi R, et al. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012;148(8):890–897.
   PubMedGoogle Scholar
• Mamolo CM, Bushmakin AG, Cappelleri JC. Application of the itch severity score in patients with moderate-to-severe plaque psoriasis: clinically important difference and responder analyses. J Dermatolog Treat. 2015;26(2):121–123.
   PubMed Web of Science ®Google Scholar
• Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169(1):137–145.
   PubMed Web of Science ®Google Scholar
• Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015;73(3):395–399.
   PubMed Web of Science ®Google Scholar
• Ranoux D, Attal N, Morain F, et al. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64(3):274–283.
   PubMed Web of Science ®Google Scholar
• Weinfeld PK. Successful treatment of notalgia paresthetica with botulinum toxin type A. Arch Dermatol. 2007;143(8):980–982.
   PubMedGoogle Scholar
• Wessler I, Reinheimer T, Kilbinger H, et al. Increased acetylcholine levels in skin biopsies of patients with atopic dermatitis. Life Sci. 2003;72(18–19):2169–2172.
   PubMed Web of Science ®Google Scholar
• Heyer G, Vogelgsang M, Hornstein OP. Acetylcholine is an inducer of itching in patients with atopic eczema. J Dermatol. 1997;24(10):621–625.
   PubMedGoogle Scholar
• Heckmann M, Heyer G, Brunner B, et al. Botulinum toxin type A injection in the treatment of lichen simplex: an open pilot study. J Am Acad Dermatol. 2002;46(4):617–619.
   PubMed Web of Science ®Google Scholar
• Gazerani P, Pedersen NS, Drewes AM, et al. Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin. Br J Dermatol. 2009;161(4):737–745.
   PubMed Web of Science ®Google Scholar
• Mishra SK, Hoon MA. Transmission of pruriceptive signals. Handb Exp Pharmacol. 2015;226:151–162.
   PubMedGoogle Scholar
• Sukhtankar DD, Ko MC. Physiological function of gastrin-releasing peptide and neuromedin B receptors in regulating itch scratching behavior in the spinal cord of mice. PLoS One. 2013;8(6):e67422.
   Google Scholar
• Mishra SK, Hoon MA. The cells and circuitry for itch responses in mice. Science. 2013;340(6135):968–971.
   PubMed Web of Science ®Google Scholar
• Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344–1354.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Randomized placebo controlled study to determine safety, pharmacodynamics and efficacy of ILV-094 in atoipc dermatitis [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT01941537?term=NCT01941537&rank=1
   Google Scholar
• Wilson SR, The L, Batia LM, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell. 2013;155(2):285–295.
   PubMed Web of Science ®Google Scholar
• Lee EB, Kim KW, Hong JY, et al. Increased serum thymic stromal lymphopoietin in children with atopic dermatitis. Pediatr Allergy Immunol. 2010;21(2 Pt 2):e457–60.
   Google Scholar
• Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3(7):673–680.
   PubMed Web of Science ®Google Scholar
• Safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT00757042?term=amg157+atopic+dermatitis&rank=1
   Google Scholar
• Kremer AE, Bolier R, van Dijk R, et al. Advances in pathogenesis and management of pruritus in cholestasis. Dig Dis. 2014;32(5):637–645.
   PubMed Web of Science ®Google Scholar
• Kremer AE, van Dijk R, Leckie P, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology. 2012;56(4):1391–1400.
   PubMed Web of Science ®Google Scholar
• Clinical trials.gov. IBAT inhibitor A2450 for cholestatic pruritus [Internet]. 2015 [cited 2015 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02360852?term=a4250&rank=1
   Google Scholar